Literature DB >> 12462295

Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis.

Monika Stender1, Lynda Bryant-Comstock, Seren Phillips.   

Abstract

BACKGROUND: Detailed assessments of the direct costs related to bipolar disorder and of the burden it places on the health care system are limited.
OBJECTIVE: In this retrospective, cross-sectional, descriptive analysis, we assessed prescription medication and other medical resource use in bipolar disorder in an insured population in the northeastern United States.
METHODS: Number and types of prescription drugs, medical encounters, and respective costs were derived from a New England insurer database for 1996. This analysis was purely descriptive in nature and no statistical comparisons were made.
RESULTS: Patients with bipolar disorder (N = 3120) were compared with a randomly selected age- and sex-matched nonbipolar population (N = 3120). A subgroup of patients with bipolar I disorder (n = 336), defined as having at least 1 hospital admission for mania, also were examined. A total of $2,803,673 was spent on all drugs for patients with bipolar disorder, who received a mean of 15 central nervous system (CNS) drug prescriptions per person, at an average cost of $582. This compares with $461,354 spent on drugs for nonbipolar patients, who received a mean of 1 CNS drug prescription per person, at an average cost of $33. Medical encounters for bipolar patients cost more than for nonbipolar patients ($16,230,840 vs $4,074,797). In patients with bipolar disorder, medical encounters for mental disorders accounted for 45.8% of costs. In nonbipolar patients, medical encounters for mental disorders accounted for 4.2% of costs. The inpatient cost for mental disorders in the bipolar patients was $4,846,311, with most of this cost (69.3%) attributed to patients with bipolar I disorder ($3,357,036).
CONCLUSIONS: The number and cost of both prescriptions and health care encounters suggest that bipolar disorder, especially bipolar I, is both difficult and costly to manage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12462295     DOI: 10.1016/s0149-2918(02)80070-4

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  12 in total

Review 1.  Quetiapine: a pharmacoeconomic review of its use in bipolar disorder.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

Review 2.  Cost-of-illness studies for bipolar disorder: systematic review of international studies.

Authors:  Huajie Jin; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

3.  Pattern of healthcare resource utilization and direct costs associated with manic episodes in Spain.

Authors:  Monica Tafalla; Luis Salvador-Carulla; Jerónimo Saiz-Ruiz; Teresa Diez; Luis Cordero
Journal:  BMC Psychiatry       Date:  2010-04-28       Impact factor: 3.630

4.  Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics.

Authors:  Joette Gdovin Bergeson; Iftekhar Kalsekar; Yonghua Jing; Min You; Robert A Forbes; Tony Hebden
Journal:  Am Health Drug Benefits       Date:  2012-09

5.  Burden of illness in bipolar depression.

Authors:  J Sloan Manning
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

6.  Improving treatment adherence in bipolar disorder: a review of current psychosocial treatment efficacy and recommendations for future treatment development.

Authors:  Brandon A Gaudiano; Lauren M Weinstock; Ivan W Miller
Journal:  Behav Modif       Date:  2008-05

7.  Quality of life among bipolar disorder patients misdiagnosed with major depressive disorder.

Authors:  A George Awad; Krithika Rajagopalan; Susan C Bolge; Diana D McDonnell
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

8.  Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review.

Authors:  Rachael L Fleurence; Mary Lou Chatterton; Julia M Dixon; Kitty Rajagopalan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

9.  Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population.

Authors:  Carolyn Harley; Hong Li; Patricia Corey-Lisle; Gilbert J L'Italien; William Carson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-06-29       Impact factor: 4.328

10.  One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.

Authors:  Edward Kim; Min You; Andrei Pikalov; Quynh Van-Tran; Yonghua Jing
Journal:  BMC Psychiatry       Date:  2011-01-07       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.